Key regions: Australia, Germany, United Kingdom, United States, France
The Immunosuppressants market in Oman has been experiencing steady growth in recent years.
Customer preferences: The demand for immunosuppressants in Oman is largely driven by patients who have undergone organ transplantation and require medication to prevent their immune system from rejecting the new organ. Additionally, there is a growing prevalence of autoimmune diseases such as rheumatoid arthritis and lupus, which also require immunosuppressant medication.
Trends in the market: One of the key trends in the immunosuppressants market in Oman is the increasing availability of generic versions of these drugs. This has led to a decrease in prices and made the medication more accessible to a wider range of patients. Another trend is the shift towards more targeted and personalized treatments, with the development of new drugs that can more specifically target the immune system without causing as many side effects.
Local special circumstances: One of the unique factors affecting the immunosuppressants market in Oman is the country's high rate of consanguineous marriages. This has led to a higher prevalence of certain genetic disorders that require immunosuppressant medication, such as thalassemia and sickle cell disease. Additionally, Oman has a relatively young population, which means that there is a growing need for immunosuppressant medication as more people are diagnosed with autoimmune diseases over time.
Underlying macroeconomic factors: The healthcare sector in Oman has been undergoing significant development in recent years, with increased investment in infrastructure and technology. This has led to improvements in access to healthcare services and medications, including immunosuppressants. Additionally, Oman has a relatively high GDP per capita compared to other countries in the region, which means that more people are able to afford the medication they need. Finally, the government of Oman has been implementing policies to encourage the growth of the pharmaceutical industry, which has helped to support the development of the immunosuppressants market in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
